A Multicenter, Randomized, Single-blind, 2-Arm Intervention Study Evaluating the Adverse Events and Quality of Life After Irreversible Electroporation for the Ablation of Localized Low-intermediate Risk Prostate Cancer. Reply.

Abstract

No AccessJournal of UrologyReply to Letters to the Editor16 Mar 2023A Multicenter, Randomized, Single-blind, 2-Arm Intervention Study Evaluating the Adverse Events and Quality of Life After Irreversible Electroporation for the Ablation of Localized Low-intermediate Risk Prostate Cancer. Reply. Kai Zhang, Jeremy Teoh, Pilar Laguna, Chi-Fai Ng, and Jean de la Rosette Kai ZhangKai Zhang Department of Urology, Beijing United Family Hospital and Clinics, Beijing, China , Jeremy TeohJeremy Teoh S.H. Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China , Pilar LagunaPilar Laguna Department of Urology, Istanbul Medipol Mega University Hospital, Istanbul, Turkey , Chi-Fai NgChi-Fai Ng S.H. Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China , and Jean de la RosetteJean de la Rosette Department of Urology, Istanbul Medipol Mega University Hospital, Istanbul, Turkey View All Author Informationhttps://doi.org/10.1097/JU.0000000000003405AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack Citations ShareFacebookLinked InTwitterEmail "A Multicenter, Randomized, Single-blind, 2-Arm Intervention Study Evaluating the Adverse Events and Quality of Life After Irreversible Electroporation for the Ablation of Localized Low-intermediate Risk Prostate Cancer. Reply.." The Journal of Urology, Publish Ahead of Print, pp. – REFERENCES 1. . A multicenter, randomized, single-blind, 2-arm intervention study evaluating the adverse events and quality of life after irreversible electroporation for the ablation of localized low-intermediate risk prostate cancer. J Urol.2023; 209(2):347-353. Link, Google Scholar 2. . Focal therapy in prostate cancer-report from a consensus panel. J Endourol. 2010; 24(5):775-780. Crossref, Medline, Google Scholar 3. . Magnetic resonance imaging-targeted biopsy may enhance the diagnostic accuracy of significant prostate cancer detection compared to standard transrectal ultrasound-guided biopsy: a systematic review and meta-analysis. Eur Urol.2015; 68(3):438-450. Crossref, Medline, Google Scholar 4. . Multiparametric MRI for prostate cancer diagnosis: current status and future directions. Nat Rev Urol.2020; 17(1):41-61. Crossref, Medline, Google Scholar 5. . Transperineal multiparametric magnetic resonance imaging-ultrasound fusion targeted prostate biopsy combined with standard template improves prostate cancer detection. J Urol.2022; 207(1):86-94. Link, Google Scholar 6. . Schema and cancer detection rates for transperineal prostate biopsy templates: a review. Ther Adv Urol.2022; 14:175628722211050. Crossref, Google Scholar 7. . EAU—EANM—ESTRO—ESUR—ISUP—SIOG guidelines on prostate cancer—2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol.2021; 79(2):243-262. Crossref, Medline, Google Scholar 8. . Effect of focal vs extended irreversible electroporation for the ablation of localized low- or intermediate-risk prostate cancer on early oncological control: a randomized clinical trial. JAMA Surg.2023. doi: 10.1001/jamasurg.2022.7516. Crossref, Google Scholar 9. . An updated systematic review on focal therapy in localized prostate cancer: what has changed over the past 5 years?Eur Urol.2022; 81(1):5-33. Crossref, Medline, Google Scholar 10. . Pair-matched patient-reported quality of life and early oncological control following focal irreversible electroporation versus robot-assisted radical prostatectomy. World J Urol.2018; 36(9):1383-1389. Crossref, Medline, Google Scholar Submitted February 26, 2023; accepted March 2, 2023; published 000. © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Kai Zhang Department of Urology, Beijing United Family Hospital and Clinics, Beijing, China More articles by this author Jeremy